Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Emerging NASH Treatments

Hear Philip N. Newsome, PhD, FRCPE, discuss the agents in late-phase clinical trials and their potential use in the treatment of NASH and fibrosis.
Philip N. Newsome, PhD, FRCPE
Released: July 1, 2020

Hear Philip N. Newsome, PhD, FRCPE, discuss the agents in late-phase clinical trials and their potential use in the treatment of NASH and fibrosis, including those in phase III such as:

  • Obeticholic acid
  • Cenicriviroc
  • Resmetirom
  • Aramchol

Download the slides from this podcast at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics/emerging-treatment-approaches/slides

See more NASH topics at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics

Information on this Educational Activity

Faculty

Philip N. Newsome, PhD, FRCPE

Professor of Hepatology
University of Birmingham
Birmingham, United Kingdom

Philip N. Newsome, PhD, FRCPE, has disclosed that he has received, on behalf of the University of Birmingham, consulting fees from Afimmune, Boehringer Ingelheim, Gilead Sciences, Intercept, Novo Nordisk, Pfizer, and Shire and funds for research support from Boehringer Ingelheim and Novo Nordisk.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Provided by the American Gastroenterology Association.

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Produced in collaboration with
Endocrine Society Logo
Supported by educational grants from
Allergan
Gilead Sciences
Intercept Pharmaceuticals, Inc.

Related Content

Hear Brent A. Neuschwander-Tetri, MD, explore NASH screening and the interplay among NAFLD, metabolic syndrome, CV risk, and diabetes risk from CCO

Brent A. Neuschwander-Tetri, MD Released: July 7, 2020

Hear Philip Newsome, PhD FRCPE, discuss available approaches to managing NASH: lifestyle, vitamin E, compounds that target insulin resistance from CCO

Philip N. Newsome, PhD, FRCPE Released: July 2, 2020

Patient cases on diagnosis, including overlooked signs and symptoms, lab and genetic tests, and more

person default Herbert L. Bonkovsky, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: March 31, 2020 Expired: March 30, 2021

Expert commentary on prevention and emerging treatment strategies for the COVID-19 pandemic from CCO

Daniel R. Kuritzkes, MD Released: March 19, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?